Fertility-Sparing Treatment for Early-Stage Cervical Cancer ≥ 2 cm: A Problem with a Thousand Nuances-A Systematic Review of Oncological Outcomes.
Carlo RonsiniMaria Cristina SolazzoNicolò BizzarriDomenico AmbrosioMarco La VerdeMarco TorellaRaffaela Maria CarotenutoLuigi CobellisNicola ColacurciPasquale De FranciscisPublished in: Annals of surgical oncology (2022)
Twenty-six studies fulfilled the inclusion criteria, and 691 patients were analyzed regarding FST. Surgery-based FST showed an RR of between 0 and 42.9%, which drops to 12.9% after excluding the vaginal or minimally invasive approaches. Furthermore, papers regarding FST based on the neoadjuvant chemotherapy (NACT) approach showed a CRR of between 21.4 and 84.5%, and an RR of between 0 and 22.2% CONCLUSION: This paper focused on the significant heterogeneity present in the clinical management of FST of ECC ≥ 2 cm. Nevertheless, from an oncological point of view, approaches limited to the minimally invasive or vaginal techniques showed the highest RR. Vice versa, the lack of standardization of NACT schemes and the wealth of confounders to be attributed to the histological features of the tumor make it difficult, if not impossible, to set a standard of treatment.
Keyphrases
- minimally invasive
- neoadjuvant chemotherapy
- robot assisted
- early stage
- end stage renal disease
- rectal cancer
- locally advanced
- newly diagnosed
- ejection fraction
- lymph node
- type diabetes
- radical prostatectomy
- single cell
- peritoneal dialysis
- prostate cancer
- radiation therapy
- coronary artery bypass
- metabolic syndrome
- young adults
- atrial fibrillation
- weight loss
- replacement therapy
- patient reported